Back to Revvity

Revvity News

RVTY

Revvity to Sell China Immunodiagnostics Assets

Revvity (RVTY) plans to sell its China Immunodiagnostics business for $200M. Analysis of impact on Diagnostics segment, FY2025 revenue mix and company risks.

4 August 2026REVVITY, INC.
All news